Cannabinoid and Psychedelic Pharmacology and Drug Development

Cannabinoid and Psychedelic Pharmacology and Drug Development

by Jim Mitchell and Google NotebookLM

Chemistry Life Sciences

Season 3

30 Day Psychedelic Pharmacology Podcast - Day 2 LSD

This episode explores the intricate pharmacology of LSD, focusing on its interactions with brain receptors, particularly 5-HT2A and 5-HT1A. The discussion breaks down how LSD acts as a partial agonist, using the analogy of a "dimmer switch" rather than an on-off mechanism. The conversation delves into the complex cellular signaling cascades triggered by LSD, including the role of G proteins and secondary messengers like IP3 and DAG, and how these molecular changes lead to altered perception and consciousness. The episode concludes by examining LSD's therapeutic potential, particularly its ability to promote neuroplasticity and facilitate psychological transformation in treating conditions like addiction, anxiety, and PTSD.

30 Day Psychedelic Pharmacology Podcast - Day 3 Psilocybin and Psilocin

This podcast episode explores the fascinating pharmacology of psilocybin and its transformation into psilocin in the brain. The discussion covers how psilocin interacts with the 5-HT2A receptor to influence mood, perception, and cognition. The hosts delve into the mechanisms behind neuroplasticity, including the role of BDNF and specific signaling pathways that contribute to potential therapeutic benefits for conditions like depression and anxiety. The conversation also examines how psilocybin affects brain networks, particularly its ability to quiet the default mode network while enhancing connectivity in other regions.

30 Day Psychedelic Pharmacology Podcast - Day 4 DMT

This podcast episode provides an in-depth exploration of DMT's pharmacology, focusing on its unique interactions with brain receptors. The discussion covers DMT's remarkably fast action through the 5-HT2A receptorand its interaction with the Sigma-1 receptor, which may play a role in neuroprotection. The hosts explore how DMT's rapid metabolism by MAO enzymes contributes to its short durationand discuss potential therapeutic applications, including research on depression, anxiety, and addiction. The episode also delves into the importance of set and setting, brain imaging studies showing DMT's effects on neural connectivity, and the development of DMT analogs for research purposes.

30 Day Psychedelic Pharmacology Podcast - Day 5 5-MeO-DMT

This podcast episode provides an in-depth exploration of 5-MeO-DMT, discussing its pharmacological mechanisms and therapeutic potential. The conversation covers how the substance interacts with serotonin receptors (5HT2A and 5HT1A), its effects on synaptic plasticity, and its uniquely rapid metabolism through MAO enzymes. The hosts examine the importance of set and setting in psychedelic experiences, citing the Borkel study from 2024 which found that natural settings and presence of loved ones led to better outcomes. The discussion also touches on safety considerations, potential risks, and the future of personalized psychedelic therapy, including possible applications of VR in therapeutic settings.

30 Day Psychedelic Pharmacology Podcast - Day 6 MDMA

This podcast episode explores MDMA's dual nature as both a therapeutic tool and recreational substance, examining its complex interactions with brain chemicals like serotonin, dopamine, and oxytocin. The discussion covers MDMA's mechanisms of action, including how it affects neurotransmitter systems, its potential therapeutic applications particularly for PTSD treatment, and important safety considerations. The episode also delves into emerging research on MDMA-assisted therapy for conditions like social anxiety in autism and its potential role in couples therapy, while emphasizing the importance of responsible use and professional guidance.

30 Day Psychedelic Pharmacology Podcast - Day 7 Ibogaine

This podcast episode provides an in-depth exploration of Ibogaine, focusing on its unique pharmacological properties and potential in addiction treatment. The discussion breaks down Ibogaine's complex mechanisms of action, particularly its effects on NMDA and kappa opioid receptors, as well as its role in modulating BDNF signaling. The hosts examine both the promising therapeutic potential and serious risks of Ibogaine treatment, including cardiac concerns and the importance of medical supervision. The episode also covers crucial aspects of treatment including set and setting, legal considerations, and the integration of psychotherapy, emphasizing that while Ibogaine shows promise, it's not a "magic bullet" for addiction.

30 Day Psychedelic Pharmacology Podcast - Day 8 Mechanisms of Action

This podcast episode explores the molecular mechanisms of psychedelic drugs, focusing on how they interact with the brain's serotonin system, particularly the 5-HT2A receptor. The discussion covers key concepts like functional selectivity, explaining how different psychedelics can produce varying effects despite targeting the same receptor. The episode delves into important brain regions and processes, including the thalamus's role as a sensory gateway, the default mode network's involvement in self-reflection, and the mysterious claustrum's function in consciousness. It also examines molecular pathways like MAP kinase and PLC-IP3, which contribute to lasting neurological changes and therapeutic potential.

30 Day Psychedelic Pharmacology Podcast - Day 9 Neuroplasticity

This podcast episode explores the molecular mechanisms of psychedelics and neuroplasticity, diving deep into how these substances interact with brain receptors, particularly the 5HT2A receptor. The discussion covers key topics including: - The role of serotonin and other neurotransmitters in psychedelic effects - How psychedelics like psilocybin can alter brain connectivity and communication between regions - The importance of set and setting in psychedelic experiences - The therapeutic potential for conditions like PTSD and depression The episode also addresses safety considerations and the current state of psychedelic research, emphasizing both the promising potential and necessary precautions in their therapeutic use.

30 Day Psychedelic Pharmacology Podcast - Day 10 The Default Mode Network

This podcast episode explores the relationship between psychedelics and the Default Mode Network (DMN) in the brain. The discussion covers how psychedelics, particularly through 5HT2A receptor activation, can reduce DMN activity. The hosts explain that the DMN functions as the brain's "idle mode" during daydreaming and self-reflection, and how psychedelics can disrupt negative thought patterns by affecting this network. They also delve into the molecular mechanisms involving glutamate and GABA neurotransmitters, while addressing important considerations about set, setting, and safety in psychedelic experiences.

30 Day Psychedelic Pharmacology Podcast - Day 11 Therapeutic Use for Depression

This podcast episode explores the therapeutic potential of psychedelics for treating depression, comparing them with traditional antidepressants. The discussion covers key mechanisms including 5HT2A receptor interactions, neuroplasticity, and the role of BDNF in brain health. The episode delves into specific psychedelics like MDMA and psilocybin, explaining their effects on brain chemistry and mood regulation. It also addresses important considerations about set and setting, potential risks, and the current state of research in psychedelic therapy.

10 of 26